PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 21, 2025Frontiers in Immunology4 citationsOpen Access

Membraneless organelles-based integrative analysis constructs an immune-related prognostic signature and identifies NRG1 as a novel methylation biomarker in colorectal cancer

View Full Paper
JCJingsong ChengNCNanting ChenQYQinan Yin

Key Points

  • A prognostic signature called MPRS is linked to tumor ecology and treatment responses in colorectal cancer patients.
  • NRG1 was identified as a crucial gene in the MPRS with downregulation associated with poor prognosis and methylation.
  • Integration of transcriptomic data and multi-omics analyses provided insights into immune microenvironment and tumor behavior.
  • The findings suggest that promoter methylation plays a key role in regulating NRG1 expression, offering potential therapeutic targets.

Abstract

Background The dysfunction of membraneless organelles (MLOs) has been implicated in tumorigenesis and progression by aberrant liquid–liquid phase separation (LLPS). However, the role of MLOs in the prognosis and tumor immune microenvironment (TIME) of colorectal cancer (CRC) remains unclear. Method We integrated transcriptomic data of MLO-related genes to identify distinct CRC subtypes and constructed a prognostic risk score termed MPRS. Then, we systematically demonstrated the characteristics of MPRS based on multi-omics analyses. We further assessed NRG1’s LLPS possibility, prognostic significance, and its correlation with methylation through comprehensive analysis and in vitro experiment. Results A prognostic signature called MPRS associated with prognosis, tumor ecotypes, genomic alterations, TIME patterns, immunotherapy responses, chemotherapy sensitivity in CRC patients. NRG1, identified as the most important MPRS gene with high predicted LLPS propensity—was significantly downregulated in CRC tissues and correlated with prognosis. Promoter methylation was found to be a crucial mechanism underlying NRG1 downregulation, which could be rescued by 5-Aza-2-deoxycytidine (Aza) treatment. The qRT-PCR, IHC and Aza treatment were utilized for in vitro validation. Conclusion Our integrated multi-omics analysis constructed the MPRS model to delineate CRC tumor ecology and identified NRG1 as a methylation biomarker with predicted phase-separation propensity, with potential therapeutic implications that warrant prospective validation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/68f74e597f21f73e19e5b364https://doi.org/10.3389/fimmu.2025.1678096
Ask AI
Helpful
Bookmark
Share
View Full Paper